Literature DB >> 16436501

Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.

Nobukazu Kakui1, Jiro Tanaka, Yuji Tabata, Kenji Asai, Naomi Masuda, Takako Miyara, Yuko Nakatani, Fukuichi Ohsawa, Naoyuki Nishikawa, Masaharu Sugai, Makoto Suzuki, Kozo Aoki, Hiroshi Kitaguchi.   

Abstract

We evaluated the pharmacological profiles of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel tetrahydrocarbazole derivative as a neuropeptide Y (NPY) Y5 receptor antagonist. This compound showed a highly selective in vitro affinity for Y5 (IC(50) = 4.3 +/- 0.4 nM) relative to other NPY receptor subtypes like Y1 or Y2. Its binding to Y5 was found to be fully antagonistic from cyclic AMP accumulation assays in human embryonic kidney 293 cells. Pharmacokinetic analysis revealed sufficient oral availability and brain permeability of this compound accompanied with clear dose relation. We attempted to assess the selectivity of FMS586 and, thereby, to infer the physiological role of Y5 in the following feeding experiments in normal rats. An intracerebroventricular injection of NPY and Y5-selective agonist peptide induced acute and robust feeding responses in satiated rats, and prior administration of FMS586 at the doses from 25 to 100 mg/kg clearly inhibited these responses by approximately 55 and 90%, respectively. This compound also showed dose-dependent but transient suppression in natural feeding models of both overnight fasting-induced hyperphagia and spontaneous daily intake. FMS586 did not modulate food intake induced by the topical injection of norepinephrine, galanin, or gamma-aminobutyric acid receptor agonist muscimol to the paraventricular nucleus. In addition, we confirmed the Y5-specific activity profile of FMS586 by immunohistochemical analysis. Taken together, we propose not only that our compound potentially expresses specific blockade of central Y5 signals but also that Y5 receptor would certainly contribute to physiological regulation of food intake in normal rats, as suggested from its origin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436501     DOI: 10.1124/jpet.105.099705

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 2.  PET Imaging of the Neuropeptide Y System: A Systematic Review.

Authors:  Inês C F Fonseca; Miguel Castelo-Branco; Cláudia Cavadas; Antero J Abrunhosa
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

Review 3.  Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.

Authors:  C K Boughton; K G Murphy
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Neuropeptide Y receptors: how to get subtype selectivity.

Authors:  Xavier Pedragosa-Badia; Jan Stichel; Annette G Beck-Sickinger
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-04       Impact factor: 5.555

5.  Discovery of a multipotent chaperone, 1-(2,6-Difluorobenzylamino)-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol with the inhibitory effects on the proliferation of prion, cancer as well as influenza virus.

Authors:  Satoshi Yamashita; Ryo Honda; Mayuko Fukuoka; Tsutomu Kimura; Junji Hosokawa-Muto; Kazuo Kuwata
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.